The World Health Organization (WHO) has launched a clinical trial of an Ebola vaccine in the Democratic Republic of Congo (DR Congo), where the country’s worst recorded outbreak has reportedly surpassed 9,700 cases and 4,600 deaths. The trial began on Friday in Bunia, the capital of Ituri Province, with the first participants receiving the Ervebo vaccine as researchers investigate protection against the Bundibugyo strain of the virus.
The trial, named Tumaini, meaning “hope” in Swahili, comes amid concerns over the lack of approved vaccines and treatments specifically targeting the Bundibugyo species of Ebola.
WHO Director-General Tedros Adhanom Ghebreyesus announced the development in a post on X, describing the trial as a source of hope for communities affected by the outbreak.
“Science gives us hope. Today, in Bunia DRC, the first participants were vaccinated in a new Ebola vaccine trial called Tumaini, which means ‘hope’ in Swahili,” Tedros said.
The study will assess the safety and effectiveness of vaccine candidates using a ring vaccination approach, which involves immunising people at high risk of infection, including contacts of confirmed cases and their contacts.
Two additional experimental vaccines designed specifically for the Bundibugyo virus are expected to join the trial. The candidates are being developed by the University of Oxford and US biotechnology company Moderna.
According to the report, the study will include pregnant women and children aged 12 and above, groups that are often excluded from clinical trials. Their inclusion could help researchers gather evidence on vaccine safety and effectiveness among populations that may face additional risks during outbreaks.
WHO emergencies director Chikwe Ihekweazu said the research could provide the first clear evidence of vaccine effectiveness against the Bundibugyo virus if the trial produces positive results.
DR Congo declared its 17th Ebola outbreak on May 15, prompting the WHO to declare a public health emergency of international concern two days later.
Researchers hope the Tumaini trial will help establish whether the vaccine candidates can protect people against the Bundibugyo strain, support efforts to control the current outbreak and improve preparedness for future Ebola emergencies.
See post:

